Individual interventions may not result in the expected efficacy.
Results of a recent study on combining orthokeratology and topical atropine 0.01%.
Results of a single masked, randomized two-year controlled clinical trial
The real value of this study, however, lies in the follow-up findings after cessation of the outdoor intervention.
Practitioners offering myopia management need to know the effect a patient’s binocular vision status has on their management strategies.
Presently, only atropine, pirenzepine, and 7-methylxanthine are shown to reduce myopia progression in human trials.
The researchers concluded that topical low-dose atropine appears to be safe and effective in a cohort of European schoolchildren.
Combined interventions for myopia will potentially influence the standard of care.
Existing evidence has failed to convince doctors to uniformly embrace treatments for myopic progression control.
A summary of the LAMP Study results
Axial elongation rate is faster in younger children undergoing ortho-k treatment.
There is a strong correlation between the amount of myopia and the length of the eye in all individuals.
When should one start atropine treatment for myopes?
Dwight Akerman, OD, MBA, FAAO, FBCLA Professor Ian Flitcroft wrote, “… there is no evidence of a safe threshold level of myopia...
By Karen Lahav-Yacouel PhD Student – Brien Holden Vision Institute Myopia is on the rise globally. Research on ways to minimise the...
By Cathleen Fedtke, Dipl. Ing. (FH), PhD, FAAO Senior Research Fellow, Project Manager – Brien Holden Vision Institute The use of the...
By Jennie Diec, BOptom (Hons) Senior Research Optometrist – Brien Holden Vision Institute Previous publications on bifocal and progressive spectacles have shown...
By Andrew D. Pucker, OD, PhD, FAAO, FSLS Assistant Professor The University of Alabama at Birmingham Are you prescribing myopia management? I...
There are a range of interventions that can reduce myopia progression.
The effect of overnight orthokeratology
While this is still a work-in-progress, I’d like to propose a blueprint.
No one treatment is 100% effective at slowing the rate of myopia progression.
Implicit in deciding when to initiate myopia management is monitoring pre-myopic patients who are at risk of developing myopia.
One of the key gaps in putting myopia management into practice is how to gauge success in your strategy.
Atropine has been the apparent hero of myopia management since the 2006 publication of the ATOM (atropine for the treatment of childhood...
Most eye care practitioners don’t routinely measure axial length in clinical practice, mainly due to lack of access to the instrumentation and...